An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer [EXTENSION OF 700012740]

Trial Profile

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer [EXTENSION OF 700012740]

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Denosumab (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Amgen
  • Most Recent Events

    • 12 Mar 2015 Last checked against ClinicalTrials.gov record.
    • 24 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Apr 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01824342).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top